ADAR

BIRAD - Research and Development Co. Ltd

ADAR inhibitors to suppress resistance to immune checkpoint inhibitors

By Assaf Sagiv / December 17, 2020 / Comments Off on ADAR inhibitors to suppress resistance to immune checkpoint inhibitors

The Problem In recent years, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system. Nevertheless, while the immune checkpoint blockade approach can induce durable responses across multiple types of malignancies, these remarkable responses…

Read More